Impact Factor
4.17
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
3.96
6,112 total citations
h5-index
69
h5 depth signal
Cited share
85.0%
1,383 of 1,628
Total citations
6,112
Citation footprint
Metric signal
3.76
External metric anchor
Self-citation
5.3%
321 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
3,042
China
1,587
United Kingdom
600
Italy
590
Germany
502
Citing Fields of Research
Neurodegenerative Disorders
7,955
Neurosciences
1,014
Palliative Care
415
Aging & Longevity
292
Genetics & Genomics
227
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
13,323
Articles tracked across the journal lifetime
Indexed publication set
1,628
1,383 cited publications
Last 12 months
978
81.5 publications/month
Open access share
23.7%
232 OA publications in the last year
Leading citing country
United States
3,042 citing publications
Leading citing field
Neurodegenerative Disorders
7,955 citing publications
Latest tracked publication
19 October 2026
10 recent records available
Coverage & Indexing History
v4n1, Feb. 2002-
v4n1, Feb. 2002-
Active Coverage
Research Focus & Classification
Indexed Subjects
Neurodegenerative Disorders
Broad Categories
Geriatrics
Neurology
Neurodegenerative Disorders
MeSH Descriptors
Alzheimer Disease
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1177/13872877261498425
Open DOI
Comparing operational definitions of screening-based cognitive impairment in the Tohoku Medical Megabank cohort: Focus on digital engagement
Background: Dementia prevention is a global health priority, yet most large-scale population studies come from Western settings. Japan, a rapidly aging society, provides a unique non-Western epidemiological context for characterizing cog...
02
DOI 10.1177/13872877261498372
Open DOI
Association between late-life blood pressure and incident dementia in older men: The Kuakini Honolulu-Asia aging study
Background: The relationship between late-life blood pressure and incident dementia (including Alzheimer's disease and vascular dementia) remains controversial. Objective: To examine whether late-life blood pressure is associated with in...
03
DOI 10.1177/13872877261498357
Open DOI
Evening chronotype and incidence of all-cause dementia and subtypes after accounting for other sleep traits: A prospective cohort study
Background: Chronotype may affect neurophysiology, but whether its association with dementia persists independent of other sleep traits remains uncertain. Objective: To examine associations of chronotype with incident dementia subtypes a...
04
DOI 10.1177/13872877261498210
Open DOI
Home-delivered transcranial direct current stimulation with or without cognitive training in mild dementia due to Alzheimer's disease
Background: Transcranial direct current stimulation (tDCS) and cognitive training are non-pharmacological interventions for cognitive impairment in Alzheimer's disease (AD), but evidence on combined protocols in mild dementia remains lim...
05
DOI 10.1177/13872877261497232
Open DOI
The critical role of PET-based assessment of cerebrovascular disease in the management of patients with cognitive impairment and dementias
A recent survey provides valuable insights into French practitioners’ preparedness for implementing anti-amyloid immunotherapy (AAI) for Alzheimer’s disease. It highlights the need for education but also underscores a broader challenge: ...
06
DOI 10.1177/13872877261497299
Open DOI
Diagnostic accuracy of plasma amyloid-β42 and Montreal Cognitive Assessment score as composite index for Alzheimer's disease in resource-limited settings: An exploratory study
Background: Accurate diagnosis of Alzheimer's disease (AD) in Indonesia remains challenging due to limited access to cerebrospinal fluid (CSF) analysis and PET imaging. Plasma amyloid-β42 (Aβ 42 ) may offer a less-invasive and affordable...
07
DOI 10.1177/13872877261497236
Open DOI
Lower cardiac output is associated with longitudinal decreases in cerebrospinal fluid amyloid-β42, a core Alzheimer's disease biomarker, in women but not men
Subclinical reductions in cardiac output relate to cognitive decline. We examined the relationship between cardiac output and cerebrospinal fluid (CSF) biomarkers of Alzheimer's disease pathologies in 153 participants from the Vanderbilt...
08
DOI 10.1177/13872877261496548
Open DOI
Locus coeruleus degeneration impairs forebrain arteriole physiology and perfusion in a rat model of Alzheimer's disease
The locus coeruleus (LC) provides forebrain norepinephrine (NE) and degenerates early in Alzheimer's disease (AD). We have shown that experimental LC lesions in the Tg344-19 AD rat model result in parenchymal arteriole (PA) stenosis, blo...
09
DOI 10.1177/13872877261496316
Open DOI
Terminal agitation in dementia: Challenges and opportunities
Terminal agitation (TA), also referred to as terminal restlessness or terminal delirium, is a complex, multifactorial clinical syndrome that occurs at the end of life. While TA is evident in dementia (including Alzheimer's disease), it i...
10
DOI 10.1177/13872877261500140
Open DOI
Immunoglobulin GM (γ marker) allotypes as potential genetic markers of efficacy of lecanemab therapy in Alzheimer's disease
Lecanemab is a humanized IgG1 monoclonal antibody that targets amyloid-β (Aβ) aggregates, a pathological hallmark of Alzheimer's disease (AD). In the largest clinical trial of its kind to date, lecanemab slowed cognitive decline by 27% i...
Bibliographical & Catalog Notes
Also issued online.
v. 1, no. 1 (Mar 1998)20021217 Notice not published Printed on acid-free paper